ADXNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Addex Therapeutics Ltd.
Financials through Q2 FY2025, quarter ended Jun 30, 2025Last filing: 20-F on May 15, 2026
$2.89+0.13 (+4.71%)
Close on Oct 19, 2026
Margins
Share of revenue, fiscal years 2016 to 2024
Operating margin
-681.8%−153.2 pts over 5 years
Growth rates
Compound annual growth to fiscal 2024
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -74.9% | -48.3% | -31.9% | – |
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2019 | FY2024 | Trend |
|---|---|---|---|---|
| Current ratio | – | 5.70 | 4.42 | |
| Interest coverage | – | -68.5× | -776.8× | |
| Capex to revenue | – | 1.0% | 0.3% | |
| Diluted shares | – | 26M | 98M |
Where the cash went
Fiscal 2020 to 2024, five years combined
Addex Therapeutics generated CHF 56.69M from operations and spent CHF 99.66K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
CHF 56.69M
Used
CHF 99.66K
Capital expenditureCHF 99.66K100%DividendsCHF 00%Share buybacksCHF 00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2024 against fiscal 2023
1of 5 tests passed in fiscal 2024. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-CHF 5.37M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-CHF 5.37M vs –
- Less leverageLong-term debt to assets fell0.0% → 0.0%
- Better liquidityCurrent ratio rose1.46 → 4.42
- No dilutionShare count did not rise74M → 98M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.19 → 0.09